Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now full pipeline

Fecal Incontinence: full-pipeline trial registry

7 of 23 indexed Fecal Incontinence trials are currently recruiting.

Corpus placement: #724 of 28,707 conditions by registered trial count.

23 US clinical trials · 7 currently recruiting · #724 of 28,707 conditions by registered trial count

Fecal Incontinence: 23 US clinical trials tracked, 7 recruiting.

Fecal Incontinence is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is James J. Peters Veterans Affairs Medical Center, running 2 of these trials.

Enrollment posture brief

Registry condition fecal-incontinence

OPEN 7 | RECR 30% | LATE 3 | EARLY 3 | RANK #724 | SPON 2

Nearest open-share peer: Clear Cell Renal Cell Carcinoma (30% recruiting · 46 trials)

Breast Cancer Stage II47.8%Advanced Non-Small-Cell Lung39.1%Anxiety Disorder30.4%Fecal Incontinence (this)30%Barrett's Esophagus26.1%
Open-enrollment share among volume-matched conditions near Fecal Incontinence

Fecal Incontinence lists 7 open slots (30% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Fecal Incontinence on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Fecal Incontinence is recruiting below its size-band peers.

    7 of 23 indexed trials (30.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Fecal Incontinence trials is spread across many organizations.

    James J. Peters Veterans Affairs Medical Center accounts for 2 of 23 trials (8.7%). 19 distinct sponsors appear on at least one study for this condition label.

  3. Most Fecal Incontinence trials plan to enrol fewer than 100 people.

    Median target enrolment is 52 among the 23 trials that report a genuine target (sentinel values excluded). 14 of those (60.9%) plan for fewer than 100 participants.

  4. Fecal Incontinence research is mostly interventional.

    18 interventional and 5 observational studies make up this index (78.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 32Phase 41

Open and recent trials

23 total, page 1 of 1

RECRUITING 5,000 participants

Indiana University Gastrointestinal Motility Diagnosis Registry

Indiana University

NCT04506593

RECRUITING NA 340 participants

Mechanisms of Improving Fecal Continence Muscles Motor Function

Medical College of Wisconsin

NCT06532123

RECRUITING NA 300 participants

Pelvic Health Electrically Evoked Recording (PEER) 2 Study

MedtronicNeuro

NCT05200923

RECRUITING NA 155 participants

Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)

The California Medical Innovations Institute

NCT05412069

RECRUITING NA 72 participants

Home Biofeedback Therapy for Dyssynergic Defecation, Fecal Incontinence and Urinary Incontinence

Augusta University

NCT05771597

RECRUITING NA 52 participants

Acute Genital Nerve Stimulation for Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury

MetroHealth Medical Center

NCT05626816

RECRUITING NA 10 participants

Autologous Muscle Fiber Fragment Injections

Wake Forest University Health Sciences

NCT05396456

ACTIVE NOT RECRUITING NA 275 participants

Fecal Incontinence Treatment (FIT) Study

Mayo Clinic

NCT03811821

ACTIVE NOT RECRUITING Phase 3 200 participants

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

Cook MyoSite

NCT05776277

ACTIVE NOT RECRUITING Phase 4 38 participants

Use of the LEVA® Pelvic Health System for Fecal Incontinence

University of Wisconsin, Madison

NCT06152224

ACTIVE NOT RECRUITING Phase 1 10 participants

Implantation of BioSphincter TM for Treatment of Severe Passive Fecal Incontinence

Cellf Bio

NCT05616208

ACTIVE NOT RECRUITING Phase 3 6 participants

Neostigmine and Glycopyrrolate by Iontophoresis

James J. Peters Veterans Affairs Medical Center

NCT06351995

COMPLETED NA 284 participants

Improving Women's Health by Using an Electronic Pelvic Floor Questionnaire

University of Wisconsin, Madison

NCT00880880

COMPLETED NA 255 participants

Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform

Cedars-Sinai Medical Center

NCT02436057

COMPLETED NA 137 participants

A Clinical Evaluation of the Eclipse™ System, a Vaginal Bowel Control (VBC) Therapy for Fecal Incontinence in Women

Pelvalon

NCT02428595

COMPLETED 80 participants

Sierra High Definition Ano-Rectal Manometry

Augusta University

NCT01300884

COMPLETED NA 35 participants

Feasibility Study of the Magnetic Anal Sphincter (FENIX System)

Torax Medical Incorporated

NCT01625221

COMPLETED 32 participants

Bladder Antimuscarinic Medication and Accidental Bowel Leakage

University of Alabama at Birmingham

NCT03543566

COMPLETED Phase 1 29 participants

Evaluation of Outcomes of Restoring Pelvic Floor Support With TOPAS in Women With Moderate Fecal Incontinence Symptoms

ASTORA Women's Health

NCT00565136

COMPLETED 28 participants

Diet and Stool Metabolites in Fecal Incontinence

University of Pennsylvania

NCT02485522

COMPLETED 21 participants

Fecal Incontinence Subtypes in Women With Pelvic Floor Disorders

University of Pennsylvania

NCT02772874

COMPLETED NA 10 participants

Incontinence Management System ICU Field Evaluation

Hill-Rom

NCT03628833

COMPLETED Early Phase 1 2 participants

Transdermal Administration by a Novel Wireless Iontophoresis Device

James J. Peters Veterans Affairs Medical Center

NCT06351852

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 3 2
Phase 4 1

Named interventions

Most-linked intervention names on Fecal Incontinence records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

I-Box by Dynatronics Device
2 trials
Combination of Neostigmine and Glycopyrrolate Drug
2 trials
e-PAQ-PF Other
1 trials
Incontinence Management System Device
1 trials
Magnetic Anal Sphincter Device
1 trials
AEGIS (Automated Evaluation of Gastrointestinal Symptoms) Other
1 trials
TOPAS Device
1 trials
Eclipse™ System Device
1 trials

US sites by state

Facility locations filed on Fecal Incontinence trials. A trial with sites in several states counts in each.

Minnesota 5 trials
Wisconsin 4 trials
Pennsylvania 4 trials
Ohio 4 trials
Georgia 4 trials
Washington 3 trials
New York 3 trials
North Carolina 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Fecal Incontinence page

23 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fecal Incontinence condition card totals 23 registered trials; most-linked intervention I-Box by Dynatronics; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.